Patients whose atrial fibrillation lasts longer than seven days and who do not respond well to drug therapy are now eligible ...

Boston Scientific (NYSE:BSX) recently achieved FDA approval to expand the FARAPULSE™ Pulsed Field Ablation (PFA) System's use, enhancing treatment options for persistent atrial fibrillation. This ...

Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, ...

Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial ...

Marlborough: Boston Scientific Corporation has announced that the company has received approval from the U.S. Food and Drug ...

Boston Scientific Corp. gained a second U.S. FDA approval for its Farapulse pulsed field ablation catheter, expanding its use into drug-refractory, symptomatic persistent atrial fibrillation (AF) in ...

On the heels of the first pulsed-field ablation device to win approval for atrial fibrillation ablation, a novel version of ...

Memorial Health System’s Department of Cardiology has announced the successful launch of the FARAPULSE Pulsed Field Ablation ...

Boston Scientific (NYSE: BSX) announced that the FDA approved an expansion to the label of its Farapulse pulsed field ...

Boston Scientific receives US FDA approval for expanded labelling of Farapulse PFA System: Marlborough, Massachusetts Tuesday, July 8, 2025, 11:00 Hrs [IST] Boston Scientific Corp ...

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARAPULSE™ Pulsed Field Ablation (PFA) ...